Sionna Therapeutics, INC Form 4 insider transactions

Sionna Therapeutics' CFO, Elena Ridloff, was granted 165,440 non-qualified stock options with an exercise price of $39.21, vesting monthly over four years.

OrbiMed Advisors LLC, a significant shareholder and director of Sionna Therapeutics, Inc., reported the sale of 33,356 shares of common stock at $44.55 per share.

Sionna Therapeutics Director Peter A. Thompson sold 33,356 shares of common stock for $44.55 per share under a pre-arranged 10b5-1 trading plan.

OrbiMed Advisors and OrbiMed Capital GP VIII LLC reported sales of Sionna Therapeutics common stock totaling 1,875 shares over three days in December 2025.

Sionna Therapeutics Director Peter A. Thompson reported the sale of 1,875 shares of common stock over three days in December 2025.

Sionna Therapeutics' Chief Legal Officer, Jennifer Fitzpatrick, exercised stock options and immediately sold 10,250 shares for a significant gain, as per a pre-arranged 10b5-1 plan.

OrbiMed Advisors and OrbiMed Capital GP VIII LLC reported the sale of 108,073 shares of Sionna Therapeutics common stock over three days in late November 2025.

A director of Sionna Therapeutics, Peter A. Thompson, reported the sale of 108,073 shares of common stock under a pre-arranged 10b5-1 trading plan.

RA Capital Management, a 10% owner and director, reported sales of Sionna Therapeutics common stock totaling 30,316 shares across multiple transactions in November 2025.

RA Capital Management and affiliated funds sold 136,351 shares of Sionna Therapeutics common stock across multiple transactions in mid-November 2025.

RA Capital Management and affiliated funds sold a significant portion of their common stock in Sionna Therapeutics, Inc. across multiple pre-scheduled transactions in late October 2025.

Sionna Therapeutics President & CEO Michael Cloonan exercised stock options and sold a significant number of common shares on October 21, 2025, under a pre-arranged 10b5-1 trading plan.

Funds associated with Sionna Therapeutics Director Bruce Booth sold 88,878 shares of common stock for approximately $3.04 million on October 21, 2025, under pre-arranged Rule 10b5-1 trading plans.

Sionna Therapeutics Director Bruce Booth, through affiliated Atlas Venture funds, sold over 286,000 shares of common stock in October 2025 under pre-arranged trading plans.

Sionna Therapeutics' President & CEO, Michael Cloonan, sold a total of 25,200 shares of common stock after exercising non-qualified stock options, executed under a Rule 10b5-1 trading plan.

Funds associated with Sionna Therapeutics Director Bruce Booth sold over 188,000 shares of common stock through pre-arranged trading plans in October 2025.

A director of Sionna Therapeutics, Bruce Booth, reported the sale of common stock through affiliated investment funds under pre-arranged trading plans.

Sionna Therapeutics' Chief Business Officer, Caroline Stark Beer, received a grant of 255,000 non-qualified stock options with an exercise price of $28.47.

Funds affiliated with Sionna Therapeutics Director Bruce Booth sold 78,693 shares of common stock for approximately $2.37 million through pre-arranged trading plans.

Sionna Therapeutics' President & CEO, Michael Cloonan, executed planned sales of common stock totaling 25,000 shares following option exercises.

Sionna Therapeutics' Chief Legal Officer, Jennifer Fitzpatrick, exercised stock options and immediately sold the resulting common stock shares as part of a pre-arranged trading plan.

Sionna Therapeutics' CFO and Head of Corporate Development, Elena Ridloff, sold common stock totaling 9,584 shares in two transactions under a pre-arranged 10b5-1 trading plan.

Sionna Therapeutics' President & CEO, Michael Cloonan, sold common stock acquired through option exercises as part of a pre-arranged 10b5-1 trading plan.

Sionna Therapeutics' CFO and Head of Corporate Development, Elena Ridloff, sold 23,416 shares of common stock over three days in late August 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Sionna Therapeutics' President & CEO, Michael Cloonan, exercised stock options and subsequently sold 25,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Sionna Therapeutics' CFO, Elena Ridloff, sold 52,000 shares of common stock for over $1.1 million through a pre-arranged Rule 10b5-1 trading plan.

TPG GP A, LLC, a significant shareholder and director of Sionna Therapeutics, Inc., increased its beneficial ownership by acquiring 60,000 shares of common stock for approximately $950,400.

RA Capital Management, a significant shareholder and director of Sionna Therapeutics, Inc., has filed a Form 4 disclosing the grant of non-qualified stock options to one of its partners serving on Sionna's board.

Sionna Therapeutics, Inc. Director Joanne L. Viney was granted 19,959 non-qualified stock options with an exercise price of $16.99, vesting by June 2026.

Peter A. Thompson, a Director and 10% Owner of Sionna Therapeutics, Inc., was granted 19,959 non-qualified stock options with an exercise price of $16.99, vesting by June 2026.